Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelors immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion.
Molecular Weight:
776.36
CAS Number:
[163706-06-7]
Formula:
C17H25Cl2F3N5O12P3S2
Target:
P2Y Receptor|||Others
T70335
* VAT and and shipping costs not included. Errors and price changes excepted
